Takahiro Yasui

Real‐World Outcomes of Olaparib in Japanese Patients With BRCA ‐Mutated Metastatic Castration‐Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status

OBJECTIVES: Metastatic castration-resistant prostate cancer has a poor prognosis. Although olaparib has demonstrated efficacy in patients with BRCA1/2 mutations, real-world data in Japanese patients remain limited. We aimed to evaluate the efficacy and safety of olaparib in patie...